BioSpace News Archive

Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company’s independently developed TIGIT monoclonal antibody (AK127) in combination with the Company’s global first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody,AK104) for the treatment of advanced or metastatic solid tumors in Australia.

David Tsur’s 40 years of Biotech experience further strengthens the Board at a critical phase of the Company’s growth.

Kintor Pharmaceutical Limited announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation.

Tokai University, Toyohashi University of Technology, Chubu University, and DENSO Corporation have been developing testing equipment to detect SARS-CoV-2 with support from the Japan Agency for Medical Research and Development (AMED)*1.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its sales for the first nine months of the year.

Cue Biopharma, Inc. announced today the publication of a research study titled “ T-Cell Receptor-specific Immunotherapeutics Drive Selective In vivo HIV and CMV- specific T-Cell Expansion in Humanized Mice ” in the peer-reviewed Journal of Chronic Infectious Diseases.

Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference

Padagis today announced the FDA approval and launch of an AB-rated generic version of Doxil® (Doxorubicin Liposome Injection) through its partnership with Ayana Pharma Ltd.

AmerisourceBergen concluded its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand, specialty, generic and consumer-product manufacturers.